SEC Form 4 · accession 0001209191-17-042399
PORTOLA PHARMACEUTICALS INC · PTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Lis
Officer — Chief Executive Officer · Director
Period of report
Jun 27, 2017
Accepted (ET)
Jun 29, 2017 · 8:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001269021
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 27, 2017 | M | 95,850 | $9.00 | A | 95,850 | D | |
| Common StockF1 | Jun 27, 2017 | M | 55,000 | $8.50 | A | 55,000 | D | |
| Common StockF1 | Jun 27, 2017 | M | 14,285 | $7.00 | A | 14,285 | D | |
| Common StockF1 | Jun 27, 2017 | M | 70,014 | $7.00 | A | 70,014 | D | |
| Common StockF1 | Jun 27, 2017 | M | 20,000 | $9.80 | A | 20,000 | D | |
| Common StockF2,F1 | Jun 27, 2017 | S | 129,271 | $54.92 | D | 125,878 | D | |
| Common StockF3,F1 | Jun 27, 2017 | S | 112,778 | $55.90 | D | 13,100 | D | |
| Common StockF4,F1 | Jun 27, 2017 | S | 13,100 | $56.57 | D | 0 | D | |
| Common StockF1 | Jun 28, 2017 | M | 14,150 | $9.00 | A | 14,150 | D | |
| CommonF5,F1 | Jun 28, 2017 | S | 14,150 | $55.35 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $9.00 | Jun 27, 2017 | M | 95,850 | D | Jul 14, 2010 | Jul 14, 2020 | Common Stock | 95,850 | 115,970 | D |
| Stock Option (Right to Buy)F1 | $8.50 | Jun 27, 2017 | M | 55,000 | D | Mar 23, 2011 | Mar 23, 2021 | Common Stock | 55,000 | 2,070 | D |
| Stock Option (Right to Buy)F1 | $7.00 | Jun 27, 2017 | M | 14,285 | D | Mar 8, 2012 | Mar 8, 2022 | Common Stock | 14,285 | 0 | D |
| Stock Option (Right to Buy)F1 | $7.00 | Jun 27, 2017 | M | 70,014 | D | Mar 8, 2012 | Mar 8, 2022 | Common Stock | 70,014 | 0 | D |
| Stock Option (Right to Buy)F1 | $9.80 | Jun 27, 2017 | M | 20,000 | D | Feb 27, 2013 | Feb 27, 2023 | Common Stock | 20,000 | 69,796 | D |
| Stock Option (Right to Buy)F1 | $9.00 | Jun 28, 2017 | M | 14,150 | D | Jul 14, 2010 | Jul 14, 2020 | Common Stock | 14,150 | 101,820 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.41 to $55.41, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.42 to $56.41, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.42 to $56.77, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.68, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4.